PatientsVille.com Logo

PANCREATITIS and Phentermine

PatientsVille

PANCREATITIS Symptoms and Causes

The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream.

Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications.

Acute Pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain.

Chronic Pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for PANCREATITIS

PANCREATITIS treatment research studies

Phentermine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Phentermine Side Effects

Pain (28)
Dyspnoea (27)
Anxiety (26)
Chest Pain (22)
Deep Vein Thrombosis (20)
Nausea (19)
Abdominal Pain (18)
Headache (16)
Blood Pressure Increased (16)
Abdominal Pain Upper (16)
Mitral Valve Incompetence (15)
Cholelithiasis (15)
Cholecystitis Chronic (14)
Pulmonary Embolism (14)
Injury (13)
Vomiting (13)
Ventricular Fibrillation (13)
Myocardial Infarction (13)
Loss Of Consciousness (12)
Dizziness (12)
Colitis Ischaemic (11)
Cardiac Arrest (11)
Gallbladder Disorder (10)
Fatigue (10)
Insomnia (10)
Cerebrovascular Accident (9)
Hypertension (9)
Arteriospasm Coronary (9)
Palpitations (8)
Confusional State (8)
Chest Discomfort (7)
Convulsion (7)
Hypotension (7)
Emotional Distress (7)
Feeling Abnormal (7)
Asthenia (6)
Abnormal Behaviour (6)
Diarrhoea (6)
Pain In Extremity (6)
Hypoaesthesia (6)
Tricuspid Valve Incompetence (6)
Hypercoagulation (5)
Alanine Aminotransferase Increased (5)
Mental Disorder (5)
Heart Rate Increased (5)
Pneumomediastinum (5)
Ventricular Tachycardia (5)
Respiratory Arrest (5)
Pyrexia (5)
Migraine (5)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Chronic pancreatitis on CT scan

Am wondering does anyone know if gliclazide causes pancreatic cancer andis it dangerous to useif you have had pancreatitis in the past.

At first I suffered nausea, then after 2 weeks developed pancreatitis - very painful and was immediately removed off Azathioprine by my specialist.

Chronic pancreatitis on CT scan

Enlarged liver, pancreatitis, gallstones....was hospitalized

Had a pancreas (pancreatitis) attack a year ago which was a week in hospital after being prescribed coversyl plus. Now I have been diagnosed as diabetic.

I am a 63 year old man who has been suffering from acute chronic pancreatitis. After approx 19 trips to the ER and 176 hospital stays with treatment in the last 2 years, an ER Doctor 3 weeks ago alerted me to the side effects of Zetia and t

I developed Pancreatitis 10/8/2009 and was in the hospital til 11/2/2009. My Amylace was 1898 and my Lypace was 579. I got pancreatitis b/c my local hospital failed to catch my gall bladder issues on 3 different occassions. First was 1/8/2009 when I

I have Chronic HepatitisC, type 1a, relatively inactive since 1988 from a blood transfusion. I passed 2 kidney stones and had an emergencycholecystectomy followed by acute pancreatitis in May 2010. My stones were calciu

I need an attorney now, I started Janumet in Jan-Feb 09 and in Aug PAIN in my back landed me in bed, it would up with Pancreatitis and after 4 months the DOCTORS said remove the Gallblatter, so they did, I am still on Janument but this is my last tim

I took one dose and experienced a bout of pancreatitis. I suffer from chronic pancreatitis and know what most of my 'triggers' are.....never thought a simple allergy medication would cause such a problem, I think I would rather suffer allergies than

PANCREATITIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Laparoscopic Cholecystectomy in Idiopathic Pancreatitis
Condition: Idiopathic Pancreatitis
Intervention: Procedure: Laparoscopic cholecystectomy
Outcome Measures: recurrence of acute Pancreatitis;   etiology of acute Pancreatitis in Finland in 2009-10
2 Unknown  EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis
Condition: Pancreatitis
Interventions: Drug: Magnesium (15 mmol/d);   Drug: ANTOX (vers.) 1.2 (300 µg organic selenium, 54000 IU beta carotene, 750 mg vitamin C, 540 IU vitamin E, 2700 mg methionine)
Outcome Measures: Reduction in the number of days of pancreatic pain during 12 continuous months of treatment.;   Disruption of activities of normal living.;   Analgesic use for pancreatic pain.;   Number of days of hospitalisation for conditions related to Pancreatitis.;   Quality of life (QoL) measures.;   Markers of inflammatory response and activity of the pancreas.;   Changes in urinary levels of magnesium, selenium, and vitamin C over the duration of the study.;   Antioxidant response as measured by urinary thiobarbituric acid levels.;   Response in patients with hereditary Pancreatitis and idiopathic chronic Pancreatitis.;   Correlate response with gene mutations underlying hereditary Pancreatitis (PRSS1, other) and idiopathic chronic Pancreatitis (SPINK1, CFTR, other).;   Data acquisition including markers of inflammatory response during acute attack of chronic Pancreatitis.
3 Not yet recruiting Bone Disease in Chronic Pancreatitis: A Complex Phenomenon
Conditions: Chronic Pancreatitis;   Osteopenia;   Osteoporosis
Intervention:
Outcome Measures: To define the prevalence of low bone density (osteopenia or osteoporosis) in patients with chronic Pancreatitis;   Prevalence of hypogonadism in patients with chronic Pancreatitis.;   Hypogonadism and/or opioid medication use are independent risk factors for low bone density in patients with chronic Pancreatitis.
4 Recruiting PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL
Conditions: Acute Lymphoblastic Leukemia;   Pancreatitis
Intervention:
Outcome Measures: Risk of Pancreatitis;   Course of Pancreatitis
5 Recruiting Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Condition: Post-ERCP Acute Pancreatitis
Interventions: Drug: Indomethacin;   Drug: Placebo
Outcome Measures: Rate of post-ERCP Pancreatitis in all patients;   Severity of post-ERCP Pancreatitis;   Post-fine needle aspiration Pancreatitis in setting of concomitant ERCP/EUS
6 Recruiting Indomethacin Decreases Post-ERCP Pancreatitis
Condition: Post ERCP Acute Pancreatitis
Interventions: Drug: Indomethacin;   Drug: 2.6-g suppository of glycerin
Outcome Measures: Post ERCP Acute Pancreatitis;   Severity of post-ERCP Pancreatitis;   Acute Pancreatitis;   Asymptomatic hyperamylasemia;   Measurement of serum amylase;   Routine laboratory examinations
7 Recruiting Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
Condition: Post-ERCP Pancreatitis
Interventions: Drug: high dose indomethacin;   Other: standard dose
Outcome Measures: frequency of Pancreatitis;   severity of Pancreatitis
8 Recruiting Study of Copeptin as a Diagnostic Marker for Acute Pancreatitis
Conditions: Acute Pancreatitis;   Pancreatitis
Intervention: Other: No intervention
Outcome Measures: Association between copeptin level and severity of Pancreatitis (according to Atlanta classification);   Comparison of copeptin with C reactive protein and procalcitonin in terms of assessing severity of Pancreatitis;   Predictive accuracy of copeptin, CRP and procalcitonin in terms of developing organ failure, necrosis and/or superinfection and mortality;   Determine whether change in copeptin level from day 0 to 2 is associated with organ failure, necrosis and/or superinfection
9 Recruiting Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Condition: Post-ERCP Acute Pancreatitis
Interventions: Drug: Pre-operational rectal Indomethacin;   Drug: Post-operational Rectal Indomethacin
Outcome Measures: Post-ERCP Pancreatitis;   Severity of Pancreatitis
10 Unknown  Efficacy of Administration of Somatostatin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Condition: Acute Pancreatitis
Interventions: Other: fisiologic serum;   Drug: somatostatin, intravenous bolus;   Drug: somatostatin
Outcome Measures: The incidence of acute post-ERCP Pancreatitis;   Identify sub-groups of patients with high risk to develop post-ERCP Pancreatitis
11 Recruiting Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis
Condition: Pancreatitis
Interventions: Other: Aggressive Intravenous Hydration Group;   Other: Standard Fluids Arm
Outcome Measures: Acute Pancreatitis;   Clinical volume overload;   Serum amylase three times the upper limit of normal;   Increased abdominal pain
12 Unknown  A Double-Blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis
Condition: Pancreatitis
Interventions: Drug: Indomethacin;   Drug: Placebo suspension
Outcome Measure: Reduction in Pancreatitis rate
13 Recruiting High Volume Lactated Ringer's Solution and Pancreatitis
Condition: Pancreatitis
Intervention: Other: Administration of Lactated Ringer's (LR) Solution
Outcome Measures: Change from Recovery in Development of Post-ERCP Pancreatitis at 5 and 29 Days;   Number of Participants with Adverse Events Related to Fluid Overload
14 Recruiting Fluid Resuscitation Goal in Early Stage of Severe Acute Pancreatitis
Condition: Pancreatitis
Interventions: Other: Goal A;   Other: Goal B
Outcome Measures: Mortality;   intra-abdominal Hypertension
15 Recruiting Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)
Condition: Acute Pancreatitis
Intervention: Drug: Rectal indomethacin 100mg one time before or after ERCP
Outcome Measures: Rate of Post-ERCP Pancreatitis;   Severity of Post-ERCP Pancreatitis
16 Recruiting Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography
Conditions: Pancreatitis, Chronic;   Autoimmune Disease
Intervention:
Outcome Measures: Scoring for visualization of the main pancreatic duct on 1.5 T and 3.0 T MRP;   Signal-to-noise ratio of the main pancreatic duct on 1.5 T and 3.0 T MRP;   The rate of concordance in the stricture type of the main pancreatic duct between MRP and ERP;   Scoring for confidence in diagnosing AIP based on MRP findings
17 Recruiting Prospective Evaluation of Idiopathic Pancreatitis: Role of Endoscopic Ultrasonography
Conditions: Gallbladder Disease;   Pancreatitis
Intervention:
Outcome Measure: Evaluation of current clinical practice for patients with idiopathic Pancreatitis
18 Recruiting Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis
Conditions: Cellular Diagnosis, Pancreatic Cancer;   Autoimmune Pancreatitis
Intervention:
Outcome Measures: Evaluating the additive benefit of Secretin MRCP in differentiating focal AIP and Pancreatic malignancy;   Efficacy of Secretin MRCP in monitoring therapeutic improvement in AIP patients on steroid trial
19 Unknown  Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis
Condition: Severe Acute Pancreatitis
Interventions: Drug: Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids;   Drug: Fat emulsion with MCT and LCT
Outcome Measures: Inflammatory markers;   Evolution of the degree of severity of acute severe Pancreatitis;   Complications of acute severe Pancreatitis
20 Unknown  The North American Pancreatitis Study
Condition: Pancreatitis
Interventions: Genetic: blood sampling;   Other: questionnaire
Outcome Measure: